AMTAGVI Drug Profile

Summary for Tradename: AMTAGVI

High Confidence Patents:	84
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for AMTAGVI

Recent Clinical Trials for AMTAGVI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Essen Biotech	PHASE1

See all AMTAGVI clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AMTAGVI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AMTAGVI Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773	10,166,257	2038-01-18	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773	10,246,670	2036-01-14	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773	10,246,698	2037-12-25	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773	10,272,113	2038-09-19	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773	10,398,734	2038-11-27	DrugPatentWatch analysis and company disclosures
Iovance Biotherapeutics, Inc.	AMTAGVI	lifileucel	Suspension	125773	10,414,995	2037-03-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for AMTAGVI Derived from Patent Text Search

No patents found based on company disclosures

International Patents for AMTAGVI

Country	Patent Number	Estimated Expiration
Australia	2020349419
China	108884558
Spain	2994499
European Patent Office	3512528
Australia	2020264325
Malaysia	202993

Market Dynamics and Financial Trajectory for AmTagvi (Amivantamab-vmjw)

Last updated: February 20, 2026

What is AmTagvi and its Therapeutic Profile?

AmTagvi (amivantamab-vmjw) is a bispecific antibody developed by Janssen Pharmaceuticals. It targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). Approved by the FDA in 2021 for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, its indication positions it within an underserved niche in lung cancer treatment.

Market Overview

Current Market Size for EGFR Exon 20 Insertion NSCLC

• Valued at approximately $400 million in 2022.
• Expected compound annual growth rate (CAGR) of 14% over 2022–2027 (source: GlobalData).
• The unmet medical need remains high, with limited targeted therapies approved for this subset.

Competitive Landscape

• AmTagvi's only direct competitor is Takeda’s TAK-788 (mobocertinib), approved by the FDA in 2021.
• Immunotherapies primarily target broader NSCLC populations but have limited efficacy for EGFR exon 20 insertions.
• AmTagvi’s bispecific mechanism offers a distinct mode of action; potential to expand into broader EGFR-mutant NSCLC.

Expansion Opportunities

• Pending approvals for first-line therapy in EGFR exon 20 mutants.
• Potential investigational use in other solid tumors expressing EGFR and MET.
• Bridge to combination therapies aimed at overcoming resistance.

Market Drivers

• High unmet need: EGFR exon 20 insertions lack effective targeted therapies, presenting a significant opportunity.
• Regulatory momentum: Fast track and breakthrough therapy designations facilitate clinical and regulatory progress.
• Biologic properties: Immunogenicity profile and safety profile favor use in recurrent settings.
• Combination strategies: Combining AmTagvi with chemotherapy or other targeted agents may enhance efficacy, expanding indications.

Challenges and Risks

• Competitive pipeline: Other biotech companies advancing alternative EGFR inhibitors.
• Pricing pressures: Biologic pricing and reimbursement constraints can limit revenue.
• Manufacturing complexity: Bispecific antibodies pose production challenges influencing supply and cost.

Financial Trajectory Analysis

Revenue Projections (2023–2027)

Year	Estimated Revenue	Key Assumptions
2023	$200 million	Launch in primary market, initial uptake moderate, price $150,000 per treatment course.
2024	$400 million	Increased adoption, expanded access, possible approval for broader indications.
2025	$700 million	Market penetration improves, potential first-line label, combination trials commence.
2026	$1.2 billion	Broader label approval, geographic expansion, integration into immuno-oncology trials.
2027	$1.8 billion	Sustained growth, potential in combination regimens, new tumor types.

Cost of Goods Sold (COGS) and R&D Allocation

• COGS margins estimated at 20–25%, typical for biologics.
• R&D expenditure focuses on expanding indication, combination trials, and pipeline development.

Profitability Outlook

• Breakeven expected by 2024 with high gross margins.
• Net profit margins could reach 30–40% by 2026 assuming optimal commercialization.

Regulatory and Reimbursement Outlook

• Market success depends on favorable payer policies, with payers increasingly favoring targeted therapies for rare subsets.
• Pricing negotiations could influence revenue, especially given the high treatment cost.

Strategic Considerations

• Partnering with academic centers for trial expansion.
• Emphasizing real-world data to support label expansion.
• Investing in manufacturing scalability for global distribution.

Key Takeaways

• AmTagvi benefits from high unmet needs in EGFR exon 20 insertion NSCLC.
• Competition is limited but intensifying, primarily from mobocertinib.
• Growth hinges on approval for broader indications and successful commercial execution.
• Financial estimates suggest robust revenue growth from 2023 to 2027, aligned with clinical and regulatory milestones.
• Strategic investments in partnerships, trials, and manufacturing are critical for long-term market positioning.

FAQs

1. What is the primary indication for AmTagvi?

   • Metastatic NSCLC with EGFR exon 20 insertion mutations.

2. How does AmTagvi compare to its competitors?

   • It uniquely combines targeting EGFR and MET with a bispecific antibody approach, differing from small-molecule inhibitors like mobocertinib.

3. What are key regulatory milestones expected?

   • Potential approval for first-line use, expansion into other tumor types, and combination therapy approvals.

4. What are main risks affecting revenue?

   • Competition, pricing constraints, manufacturing complexities, and regulatory delays.

5. What is the outlook for global expansion?

   • Likely once approved domestically, with strategic partnerships to accelerate international access.

References

[1] GlobalData. (2022). NSCLC market analysis.
[2] FDA. (2021). AmTagvi prescribing information.
[3] BioBusiness Reports. (2023). Biologics market outlook.
[4] IMS Health. (2022). Oncology drug pricing and reimbursement policies.
[5] Industry analyst reports. (2023). Bi-specific antibody development trends.

---